Antithrombotic Strategies and Device Thrombosis
Cardiology Clinics, ISSN: 0733-8651, Vol: 36, Issue: 4, Page: 541-550
2018
- 15Citations
- 47Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- 15
- CrossRef6
- Captures47
- Readers47
- 47
Review Description
Despite improvements in left ventricular assist device (LVAD) technology, bleeding and thrombotic complications are major concerns that adversely influence morbidity and mortality. Current antithrombotic therapy recommendations for LVAD thrombosis prophylaxis are largely derived from clinical device trials that implement a one-size-fits-all strategy. Objective serial laboratory-based assessment of thrombogenicity is needed to balance the risk of bleeding and thrombotic complications. Finally, the newest-generation device, the HeartMate 3, has been associated with lower levels of shear and reduced hemolysis that may mitigate thrombotic event occurrences.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0733865118308518; http://dx.doi.org/10.1016/j.ccl.2018.06.008; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85053332582&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/30297071; https://linkinghub.elsevier.com/retrieve/pii/S0733865118308518; https://dx.doi.org/10.1016/j.ccl.2018.06.008
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know